Dividend investing is not only about finding companies that distribute cash to shareholders. Investors also look for businesses with strong operations, improving outlooks, and potential catalysts that could influence future performance.
July brings several dividend-paying companies into focus as analysts review earnings expectations, growth strategies, and sector trends. These companies come from different parts of the economy, giving investors exposure to airlines, pharmaceuticals, restaurants, homebuilding, and consumer retail.
Here are five dividend stocks attracting attention this month.
Delta Air Lines Gains Altitude as Airline Optimism Builds
Delta Air Lines, Inc. (NYSE: DAL) continues to draw attention as analysts evaluate the future strength of the airline industry.
Citi raised its price target for Delta Air Lines from $79 to $106 on June 26 and maintained its Buy rating. The firm said its second-quarter airline outlook suggested that many companies in the sector could exceed expectations and provide third-quarter guidance above current market estimates.
However, Citi also noted that some of the positive expectations may already be reflected in recent stock performance.
Barclays also raised its price target on Delta from $85 to $105 on June 25 while maintaining an Overweight rating.
The firm said airlines could benefit from stronger third-quarter unit revenue trends. Barclays also pointed to lower energy prices and continued travel demand as factors that could support better margins.
Delta Air Lines provides scheduled passenger and cargo transportation across the United States and international markets.
AbbVie Expands Its Healthcare Reach With Skyrizi Pediatric Approval
AbbVie Inc. (NYSE: ABBV) continues to strengthen its biopharmaceutical portfolio as Skyrizi expands its patient base.
In late June, AbbVie confirmed that U.S. regulators cleared Skyrizi for children aged 6 and older living with moderate-to-severe plaque psoriasis or active psoriatic arthritis.
The approval also introduced a 55 mg pre-filled syringe option for children weighing under 40 kg, or about 88 pounds. Heavier patients can continue using the existing 150 mg syringe or pen formulation.
The pediatric expansion is important because psoriasis can begin early in life. AbbVie has noted that a meaningful portion of psoriasis patients first experience symptoms before adulthood.
Beyond pediatric use, Skyrizi remains part of AbbVie’s broader immunology portfolio, with approvals across several inflammatory conditions in adults, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
AbbVie is a global biopharmaceutical company focused on developing and commercializing treatments across immunology, oncology, neuroscience, aesthetics, and other therapeutic areas.
Darden Restaurants Shows the Power of Strong Brands
Darden Restaurants, Inc. (NYSE: DRI) is attracting attention as investors assess how large restaurant operators are performing in a challenging consumer environment.
On June 26, Piper Sandler lifted its price target on Darden from $208 to $212 while maintaining a Neutral rating. The firm said Darden’s fourth-quarter performance and initial fiscal 2027 outlook were broadly consistent with expectations.
Darden reported fiscal fourth-quarter total sales of $3.72 billion, up 13.7% from the prior year. Same-restaurant sales increased 4.6%, supported by strong performance at LongHorn Steakhouse and continued improvement at Olive Garden.
The company also raised its quarterly dividend by 8% to $1.62 per share and approved a new $1.5 billion share repurchase program.
BTIG also increased its price target on Darden from $225 to $235 while keeping a Buy rating. The firm said Darden’s comparable sales were better than expected, helped by strong customer traffic across income groups despite broader pressure on consumer spending.
Darden operates one of the largest full-service restaurant portfolios in the United States. Its brands cover Italian dining, steakhouse concepts, seafood, casual dining, and fine dining, giving the company broad exposure across multiple restaurant categories.
Lennar Faces Housing Pressure While Improving Key Metrics
Lennar Corporation (NYSE: LEN) remains in focus as investors monitor how the homebuilder is responding to a softer housing market.
On June 16, UBS reduced its price target on Lennar from $107 to $94 while keeping a Neutral rating. JPMorgan also lowered its target from $80 to $77 and maintained an Underweight rating.
The cuts followed concerns that the spring selling season was weaker than expected, leading Lennar to trim its fiscal 2026 home delivery outlook.
Even with that pressure, the company reported several operating metrics that indicated stability. Lennar delivered 20,519 homes in the second quarter, while new orders came in at 21,749 homes. The company also reported a homebuilding gross margin of 15.6%.
One encouraging development was the decline in sales incentives. Incentives on delivered homes fell to 12.9% in the second quarter, compared with 14.1% in the first quarter and 14.5% in the fourth quarter of 2025.
Lennar also announced leadership updates in June, naming Jim Parker as Chief Operating Officer and David Grove as Executive Vice President of Homebuilding.
The company builds homes, provides mortgage financing, offers title services, and develops multifamily rental properties.
Casey’s General Stores Builds a Bigger Growth Story
Casey’s General Stores, Inc. (NASDAQ: CASY) is attracting investor attention as the company continues expanding its convenience store business.
On June 25, RBC Capital raised its price target on Casey’s from $794 to $850 while maintaining a Sector Perform rating.
The firm said Casey’s Investor Day showed confidence in the company’s leadership and future strategy. RBC said the company’s projected 8%-10% EBITDA CAGR through fiscal 2029 appears achievable, driven by strong momentum, planned investments, and growth opportunities.
Goldman Sachs also increased its price target on Casey’s from $695 to $795 while maintaining a Neutral rating.
The firm said Casey’s 8%-10% EBITDA growth target could prove conservative. Goldman Sachs highlighted how the company has used its scale to balance volume growth and margin performance.
Casey’s also laid out a three-year plan targeting 8% to 10% annual EBITDA growth from fiscal 2027 through fiscal 2029, at least 400 additional stores, and about $2 billion in free cash flow.
Casey’s General Stores and its subsidiaries operate approximately 2,900 convenience stores across 19 states.
The Dividend List That Could Surprise Investors This July
The strongest dividend opportunities often appear when investors look beyond yield alone.
Delta is benefiting from improved airline optimism and travel demand. AbbVie is expanding its healthcare portfolio. Darden is showing the strength of its restaurant brands. Lennar is working through housing-market challenges while improving key metrics. Casey’s continues building its long-term expansion story.
These companies represent different parts of the economy, but each has a development that could influence how investors view its future.
For dividend-focused investors, July could be an important month to watch these names closely.
